Molecular pathophysiology and disease-modifying therapies for spinal and bulbar muscular atrophy

Archives of Neurology

Volumn 69, Issue 4, 2012, Pages 436-440

  Katsuno, Masahisa ^a   Banno, Haruhiko ^a,b   Suzuki, Keisuke ^a   Adachi, Hiroaki ^a   Tanaka, Fumiaki ^a   Sobue, Gen ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYL 1,7 BIS(3,4 DIMETHOXYPHENYL) 1,4,6 HEPTATRIEN 3 ONE; ANDROGEN RECEPTOR; BUTYRIC ACID; CURCUMIN; DUTASTERIDE; LEUPRORELIN; PLACEBO; POLYGLUTAMINE; RAPAMYCIN; TANESPIMYCIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ANDROGEN RECEPTOR GENE; BIOACCUMULATION; CAG REPEAT; CLINICAL FEATURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GENE MUTATION; GENE OVEREXPRESSION; GENETIC CODE; HOMOZYGOTE; HUMAN; INTRACELLULAR SIGNALING; KENNEDY DISEASE; MITOCHONDRIAL TOXICITY; MOLECULAR PATHOLOGY; MYOPATHY; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN DNA BINDING; PROTEIN SYNTHESIS INHIBITION; RECEPTOR GENE; REVIEW; TESTOSTERONE RELEASE; TRANSCRIPTION REGULATION;

AXONAL TRANSPORT; BULBO-SPINAL ATROPHY, X-LINKED; HUMANS; LIGANDS; MALE; PEPTIDES; RECEPTORS, ANDROGEN; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84859947798     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.2308     Document Type: Review

References (38)

1. Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset: a sex-linked recessive trait. Neurology . 1968;18 (7):671-680.
2. Katsuno M, Adachi H, Waza M, et al. Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA). Exp Neurol. 2006;200 (1):8-18. (Pubitemid 44080751)
3. Finsterer J. Perspectives of Kennedy's disease. J Neurol Sci. 2010;298(1-2):1-10.
4. Atsuta N, Watanabe H, Ito M, et al. Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain. 2006;129(pt 6):1446-1455. (Pubitemid 43999377)
5. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991;352(6330):77-79. (Pubitemid 21896702)
6. Sobue G, Hashizume Y, Mukai E, Hirayama M, Mitsuma T, Takahashi A. X-linked recessive bulbospinal neuronopathy: a clinicopathological study. Brain. 1989; 112(pt 1):209-232. (Pubitemid 19056483)
7. Poletti A. The polyglutamine tract of androgen receptor: from functions to dysfunctions in motor neurons. Front Neuroendocrinol. 2004;25(1):1-26. (Pubitemid 38744538)
8. Parodi S, Pennuto M. Neurotoxic effects of androgens in spinal and bulbar muscular atrophy. Front Neuroendocrinol. 2011;32(4):416-425.
9. Adachi H, Katsuno M, Minamiyama M, et al. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain. 2005; 128(pt 3):659-670. (Pubitemid 40380200)
10. Takeyama K, Ito S, Yamamoto A, et al. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron. 2002;35(5):855-864.
11. Montie HL, Cho MS, Holder L, et al. Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet. 2009;18(11):1937-1950.
12. Schmidt BJ, Greenberg CR, Allingham-Hawkins DJ, Spriggs EL. Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology. 2002;59(5):770-772.
13. Katsuno M, Adachi H, Kume A, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron. 2002;35(5):843-854.
14. Chevalier-Larsen ES, O'Brien CJ, Wang H, et al. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci. 2004;24(20):4778-4786. (Pubitemid 38668202)
15. Palazzolo I, Stack C, Kong L, et al. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron. 2009; 63(3):316-328.
16. Nedelsky NB, Pennuto M, Smith RB, et al. Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron. 2010;67(6):936-952.
17. Orr CR, Montie HL, Liu Y, et al. An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. J Biol Chem. 2010;285(46):35567-35577.
18. Minamiyama M, Katsuno M, Adachi H, et al. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet. 2004;13(11):1183-1192. (Pubitemid 38787000)
19. Sopher BL, Thomas PS Jr, LaFevre-Bernt MA, et al. Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration. Neuron. 2004;41(5):687-699. (Pubitemid 38326832)
20. Katsuno M, Adachi H, Minamiyama M, et al. Disrupted transforming growth factorbeta signaling in spinal and bulbar muscular atrophy. J Neurosci. 2010;30(16):5702-5712.
21. Ranganathan S, Harmison GG, Meyertholen K, Pennuto M, Burnett BG, Fischbeck KH. Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Hum Mol Genet. 2009;18(1):27-42.
22. Young JE, Garden GA, Martinez RA, et al. Polyglutamine-expanded androgen receptor truncation fragments activate a Bax-dependent apoptotic cascade mediated by DP5/Hrk. J Neurosci. 2009;29(7):1987-1997.
23. Yu Z, Dadgar N, Albertelli M, et al. Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J Clin Invest. 2006;116(10):2663-2672. (Pubitemid 44511630)
24. Monks DA, Johansen JA, Mo K, et al. Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. Proc Natl Acad Sci U S A. 2007;104(46):18259-18264. (Pubitemid 350210854)
25. Morfini G, Pigino G, Szebenyi G, You Y, Pollema S, Brady ST. JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport. Nat Neurosci. 2006;9(7):907-916. (Pubitemid 43980505)
26. Katsuno M, Adachi H, Minamiyama M, et al. Reversible disruption of dynactin 1-mediated retrograde axonal transport in polyglutamine-induced motor neuron degeneration. J Neurosci. 2006;26(47):12106-12117. (Pubitemid 44808377)
27. Kemp MQ, Poort JL, Baqri RM, et al. Impaired motoneuronal retrograde transport in two models of SBMA implicates two sites of androgen action [published online August 26, 2011]. Hum Mol Genet. doi:10.1093/hmg/ddr380.
28. Malik B, NirmalananthanN,Bilsland LG, et al. Absence of disturbed axonal transport in spinal and bulbar muscular atrophy. Hum Mol Genet. 2011;20(9):1776-1786.
29. Katsuno M, Adachi H, Doyu M, et al. Leuprorelin rescues polyglutaminedependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med. 2003;9(6):768-773. (Pubitemid 36749228)
30. Banno H, Katsuno M, Suzuki K, et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol. 2009;65(2):140-150.
31. Katsuno M, Banno H, Suzuki K, et al; Japan SBMA Interventional Trial for TAP-144-SR (JASMITT) study group. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): amulticentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(9):875-884.
32. Fernández-Rhodes LE, Kokkinis AD, White MJ, et al. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol. 2011;10(2):140-147.
33. Yang Z, Chang YJ, Yu IC, et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med. 2007;13(3):348-353. (Pubitemid 46376683)
34. Pandey UB, Nie Z, Batlevi Y, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature. 2007;447(7146): 859-863. (Pubitemid 46920134)
35. Waza M, Adachi H, Katsuno M, et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med. 2005;11(10):1088-1095. (Pubitemid 41486831)
36. Tokui K, Adachi H, Waza M, et al. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum Mol Genet. 2009;18(5):898-910.
37. Adachi H, Waza M, Tokui K, et al. CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. J Neurosci. 2007;27(19):5115-5126. (Pubitemid 46741791)
38. Katsuno M, Sang C, Adachi H, et al. Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc Natl Acad Sci U S A. 2005;102(46):16801-16806. (Pubitemid 41688857)